Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Idifarma Makes Serialization Investment | Contract Pharma

What are you searching for?

Sign in
Breaking News

Idifarma Makes Serialization Investment

Equipment to be operational six months ahead of the EU FMD deadline

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Spanish contract development and manufacturing organization (CDMO) Idifarma said it will meet upcoming EU serialization regulations with a €200,000 investment.

The investment will include the installation of the Antares Vision Print&Check EVO-TE carton serialization station at its EU-GMP approved plant in Pamplona, Spain and comes ahead of the EU Falsified Medicines Directive’s (EU FMD) February 2019 deadline for the serialization of licensed drug products.

The industry-wide EU FMD regulation is a legal requirement for all pharmaceutical companies intended to improve traceability of drugs, help in the fight against counterfeit products entering the supply chain and ultimately improve patient safety.

“Recognizing our role in combatting counterfeit medicines and supporting our customers with new regulatory requirements, we’ve taken a proactive approach and have been preparing for the arrival of this legislation for a long time now,” said Luis Oquiñena, general manager and co-founder, Idifarma. “We have worked closely with the manufacturers of this machine and track and trace software vendors to specify our requirements according to our clients’ needs across the world. This machine offers us the flexibility to upgrade for future regulatory or client requirements and will enable us to help protect our clients’ products and the public against counterfeit pharmaceuticals.”

The company anticipates that the equipment will be operational six months ahead of the EU FMD deadline. 

Mr. Oquiñena, said, “Our investment will offer real support to our clients as they too prepare to meet the regulations. We will be able to serialize commercial batches manufactured by Idifarma for clients, but we will also be able to offer standalone serialization services as an outsourcing partner. As the deadline draws closer we fully expect to see demand for these specialized outsourced services to increase.”

The investment in serialization follows the expansion of its capsule filling capabilities in 2017.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics